Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: Prevalence, associated factors, and impact on quality of life

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2596-2600

  Akechi, Tatsuo ^a   Okuyama, Toru ^a   Endo, Chiharu ^a   Sagawa, Ryuichi ^a   Uchida, Megumi ^a   Nakaguchi, Tomohiro ^a   Sakamoto, Masaki ^a   Komatsu, Hirokazu ^b   Ueda, Ryuzo ^b   Wada, Makoto ^c   Furukawa, Toshiaki A ^a  

^a NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RITUXIMAB; TEGAFUR; TRASTUZUMAB; VINCRISTINE;

ADULT; AGE; AMBULATORY CARE; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; DISEASE SEVERITY; DISTRESS SYNDROME; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ C30; FEMALE; FUNCTIONAL STATUS; GENDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORROW ASSESSMENT OF NAUSEA AND EMESIS SCALE; PERSONAL NEEDS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SHORT FORM SUPPORTIVE CARE NEEDS SURVEY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 78449290686     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01718.x     Document Type: Article

References (32)

1. Morrow GR, Roscoe JA, Hynes HE, Flynn PJ, Pierce HI, Burish T. Progress in reducing anticipatory nausea and vomiting: a study of community practice. Support Care Cancer 1998; 6: 46-50.
2. Bovbjerg DH, Redd WH, Jacobsen PB et al. An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosom Med 1992; 54: 623-37.
3. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998; 6: 244-7.
4. Watson M, Meyer L, Thomson A, Osofsky S. Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 1998; 34: 831-7.
5. Chin SB, Kucuk O, Peterson R, Ezdinli EZ. Variables contributing to anticipatory nausea and vomiting in cancer chemotherapy. Am J Clin Oncol 1992; 15: 262-7.
6. Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage 1991; 6: 215-23.
7. Nerenz DR, Leventhal H, Easterling DV, Love RR. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J Clin Oncol 1986; 4: 224-33.
8. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984; 2: 1170-6.
9. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-8.
10. Hughson AV, Cooper AF, McArdle CS, Smith DC. Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J (Clin Res Ed) 1986; 293: 1268-71.
11. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-24.
12. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 549-58.
13. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-94.
14. Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-95.
15. De Boer-Dennert M, De Wit R, Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76: 1055-61.
16. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95: 155-63.
17. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006; 4: 3-8.
18. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000; 20: 113-21.
19. Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK. How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 2008; 113: 654-61.
20. Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2005; 2: 181-7.
21. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin 1989; 39: 89-104.
22. Roila F, Fatigoni S. New antiemetic drugs. Ann Oncol 2006; 17(Suppl 2): ii96-100.
23. Morrow GR. A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer Suppl 1992; 19: S72-4.
24. Brearley SG, Clements CV, Molassiotis A. A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 2008; 16: 1213-29.
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
26. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y. Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol 1998; 28: 333-8.
27. McElduff P, Boyes A, Zucca A, Girgis A. Supportive Care Needs Survey: A Guide to Administration, Scoring and Analysis. Callaghan, Australia: The University of Newcasle; 2004.
28. Okuyama T, Akechi T, Yamashita H et al. Reliability and validity of the Japanese version of the short-form supportive care needs survey questionnaire (SCNS-SF34-J). Psychooncology 2009; 18: 1003-10.
29. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
30. Kobayashi K, Takeda F, Teramukai S et al. A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 1998; 34: 810-5.
31. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26: 5618-29.
32. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-47.